Clinical Trials Directory

Trials / Completed

CompletedNCT01561807

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

A Phase 2a, Randomized, Double-Blind,Placebo-Controlled Study to Investigate the Effects of VX-787 Administered to Adult Volunteers Experimentally Inoculated With Live Influenza Virus

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
140 (actual)
Sponsor
Vertex Pharmaceuticals Incorporated · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine the antiviral activity and safety of VX-787 given to healthy adult volunteers that have been inoculated with the influenza virus.

Conditions

Interventions

TypeNameDescription
DRUGVX-787
DRUGPlacebo

Timeline

Start date
2012-03-01
Primary completion
2012-10-01
First posted
2012-03-23
Last updated
2016-09-02

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01561807. Inclusion in this directory is not an endorsement.